BiotechTV - News
by BiotechTV
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 20 chart positions in 20 markets.
By chart position
- 🇺🇸US · Life Sciences#7930K to 100K
- 🇬🇧GB · Life Sciences#1465K to 30K
- 🇸🇪SE · Life Sciences#4730K to 100K
- 🇪🇸ES · Life Sciences#6210K to 30K
- 🇰🇷KR · Life Sciences#8410K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
36K to 129K🎙 Daily cadence·420 episodes·Last published 2d ago - Monthly Reach
Unique listeners across all episodes (30 days)
121K to 431K🇺🇸23%🇸🇪23%🇬🇧7%+17 more - Active Followers
Loyal subscribers who consistently listen
36K to 129K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Pareto Securities Healthcare Conference: Sedana Medical's inhaled sedative drug/device combo is currently in front of FDA - they hope to change the ICU with it
Sep 2, 2026
Unknown duration
Pareto Securities Healthcare Conference: Pareto's Dan Akschuti highlights the innovation coming out of the Nordics region and companies that have filings in front of FDA
Sep 2, 2026
Unknown duration
Congressman Jake Auchincloss discusses the economic impact of biotech, global competition, and efforts he is taking to solidify funding, modernize regulation, and keep the United States on top
Sep 2, 2026
Unknown duration
Pareto Securities Healthcare Conference: BioInvent believes that it has found the next big checkpoint in TNFR2 - this summer they had data both in solid and liquid tumors
Sep 2, 2026
Unknown duration
Pareto Securities Healthcare Conference: Orexo believes that nasal delivery is superior to other modalities for most uses - they plan to file their naloxone program with FDA immanently
Sep 2, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 9/2/26 |  Pareto Securities Healthcare Conference: Sedana Medical's inhaled sedative drug/device combo is currently in front of FDA - they hope to change the ICU with it | CEO Johannes Doll describes what he believes are the advantages of an inhaled sedative vs the traditional IV. The company already has experience commercializing this in Europe, with 1 out of 7 ICU patients in Germany currently using it. The U.S. PDUFA date is April 16. | — | ||||||
| 9/2/26 |  Pareto Securities Healthcare Conference: Pareto's Dan Akschuti highlights the innovation coming out of the Nordics region and companies that have filings in front of FDA | He says that capital is returning to the sector and that investors have been doing more scientific due diligence recenetly. Plus, the impact of AI on biotech. | — | ||||||
| 9/2/26 |  Congressman Jake Auchincloss discusses the economic impact of biotech, global competition, and efforts he is taking to solidify funding, modernize regulation, and keep the United States on top | Interviewed by MassBio CEO Kendalle Burlin O'Connell, Congressman Auchincloss of Massachusetts describes the impact he believes a tightening of funding for basic research is having on our industry and measures he would take to bolster innovative research. He advocates for making it easier to run early stage clinical trials in the U.S. and for it to be less costly for small biotech companies to engage with FDA. | — | ||||||
| 9/2/26 |  Pareto Securities Healthcare Conference: BioInvent believes that it has found the next big checkpoint in TNFR2 - this summer they had data both in solid and liquid tumors | CEO Martin Welschof walks us through recent ASCO (ovarian in combo with Keytruda) and EHA (CTLC) data for BI-1808, and describes why the company believes TNFR2 is a compelling checkpoint with wide applicability. Plus, BI-1206 (FcyRIIB), which will have NCSLC data later this year and BioInvent ultimately hopes to partner. | — | ||||||
| 9/2/26 |  Pareto Securities Healthcare Conference: Orexo believes that nasal delivery is superior to other modalities for most uses - they plan to file their naloxone program with FDA immanently | CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Orexo also has plans for a nasal spray GLP and vaccines. | — | ||||||
| 9/2/26 |  Pareto Securities Healthcare Conference: Hansa Biopharma has a December 19 PDUFA date with FDA for its IgG depleting therapy that hopes to make more patients eligible for kidney transplant | CEO Renée Aguiar-Lucander describes the idea behind imlifidase and discusses the trial that led to the U.S. filing. Hansa has also recently confidentially filed for an IPO in the United States as well. | — | ||||||
| 9/2/26 |  Pareto Securities Healthcare Conference: Mendus' cellular immunotherapy has been making progress in numerous cancers - being thoughtful about the setting and goal of treatment have been keys | CEO Erik Manting describes vididencel and the progress the company has been making in AML, CML, and ovarian cancer. Additional CML data is expected in this second half of the year. | — | ||||||
| 9/1/26 |  A focus on cutting edge science and a busy year of presentations and partnerships has made Circio not just one of the fastest growing biotech companies in the Nordic region, but in all of Europe | Co-Founder & CEO Erik Wiklund highlights the potential of circular RNA and walks us through the work Circio is doing in gene and cell therapy, including heart and eye indications, CNS, and in vivo CAR-T. The company has raised approximately $65M USD this year, putting at the top of European biotech raises. | — | ||||||
| 9/1/26 |  Sweden's BioArtic founded the science behind the Alzheimer's medicine Leqembi - 2026 has been busy with a Parkinson's program and a host of partnerships for it brain transporter technology advancing | CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in numerous prestigious pharma partnerships. | — | ||||||
| 8/26/26 |  Remix Therapeutics announced earlier this summer plans to go public via a reverse merger - it's on the back of clinical data that was presented for its RNA modulator at ASCO | Co-Founder and CEO Pete Smith describes how Remix uses small molecules to stop the transcription of disease causing mRNAs. The lead program targets MYB and is in a phase 1/2 for adenoid cystic carcinoma. The reverse merger could close towards the end of year. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 8/26/26 |  Two fathers of children with rare diseases talk about starting biotech companies to try to create new therapies for their family members and others | Interviewed by MassBio CEO Kendalle Burlin O'Connell, Ilan Ganot describes co-founding Solid Biosciences in honor of his child with Duchenne muscular dystrophy and Daniel Fischer discusses co-founding Tevard Biosciences in honor of his child with Dravet syndrome. | — | ||||||
| 8/6/26 |  LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants | Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well. | — | ||||||
| 7/27/26 |  U.S. Science Summit: Biotech veteran Harvey Berger presents an overview of the history of Kendall Square and what is at stake to keep it a leader in life sciences | Dr. Berger, who founded Ariad Pharmaceuticals here in 1991, describes Kendall's transition from candy factories, to Polaroid, to what it is today. | — | ||||||
| 7/27/26 |  U.S. Science Summit: Patient perspectives with sickle cell patient advocate Jimi Olaghere and cystic fibrosis advocate Bob Coughlin | Jim Olaghere describes signing up for a gene editing treatment clinical trial for sickle cell disease and how it has enabled him to climb mountains and Bob Coughlin recounts the moment when a therapy became available for his son's cystic fibrosis. | — | ||||||
| 7/27/26 |  U.S. Science Summit: Curie.Bio Chairman Alexis Borisy and Parabilis Medicines CEO Mathai Mammen discusses the funding environment for biotech and communicating their work to the public | Alexis Borisy recounts the story of Revolution Medicines, which delivered the pancreatic cancer breakthrough this year, and talks about the health of the founder led side of the biotech sector. Mathai Mammen recently took Parabilis public in the largest IPO in biotech history, and describes the science that made it possible. | — | ||||||
| 7/27/26 |  U.S. Science Summit: Flagship Pioneering Founder & CEO Noubar Afeyan discusses his early days in Cambridge and the opportunities it afforded him, science communication, immigrants, and more | He describes how science 'keeps you young' because it always based on what you don't know. He urges scientists to stay humble when talking about science to the public because things can change, and he shares stories from his career and offers advice on how to keep the United States globally competitive. | — | ||||||
| 7/23/26 |  U.S. Science Summit: "Who will shape the future of Bio?" with Recursion President & CEO Najat Khan | Interviewed by HSBC Innovation Banking's Katherine Andersen, Najat Khan discusses AI, her priorities upon taking the role of CEO at Recursion earlier this year, encouraging employees to speak more than just one language of expertise, and women in leadership. | — | ||||||
| 7/23/26 |  U.S. Science Summit: Three science communicator social media all-stars share their stories and offer advice on how to tell science stories that resonate with a broad audience | Moderated by BiotechTV's Chloe Kirk, Gabriel Astorga (@GoodOlGab), Maynard Okereke (@HipHopScienceShow), and Alex Dainis (@AlexDainis) describe how the got started posting about science on social media and how they grew their audiences to what they are today. Plus, advice for companies and scientists about how to resonate the best. | — | ||||||
| 7/23/26 |  U.S. Science Summit: BiotechTV's Science Correspondent Chloe Kirk introduces the audience to the science communicator social media all-stars who were in attendance at the summit | The combined following of the group reaches approximately 3 million people on Instagram and TikTok. | — | ||||||
| 7/23/26 |  U.S. Science Summit: Listen to BiotechTV founder Brad Loncar's opening remarks at the inaugural U.S. Science Summit | He describes the format and goals of the event. | — | ||||||
| 7/22/26 |  U.S. Science Summit: Three leading biotech CEOs share the latest on biotech innovation and discuss how the United States can stay on top of an increasingly competitive global landscape | Moderated by MassBio CEO Kendalle Burlin O'Connel, Kymera Therapeutics CEO Nello Mainolfi, CRISPR Therapeutics CEO Samarth Kulkarni, and Ginkgo Bioworks CEO Jason Kelly discuss their companies' innovations (protein degradation, CRISPR gene editing, and autonomous labs), how the U.S. can increase its competitiveness, and the 'Why' that motivates them each day. | — | ||||||
| 7/22/26 |  U.S. Science Summit: Dr. Elias Zerhouni discusses the source of what made the United States strong in medical research decades ago and what is at stake to keep supporting it today | Dr. Zerhouni, the Founder and Chair of ModeX Therapeutics and Former NIH Director, talks about investments in science that started with Vannevar Bush, current day NIH funding, adding a political element to the grant making process, science communication, and more. | — | ||||||
| 5/31/26 |  ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs | The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world. | — | ||||||
| 5/31/26 |  ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications | Dr. Mark Goldsmith of Revolution Medicines describes the benefit seen by advanced patients who received the pancreatic cancer pill daraxonrasib vs those in a control group of investigator's choice standard-of-care chemotherapy, and he discusses the medicine's side effect profile. Plus, next steps for this treatment in pancreatic cancer and beyond. | — | ||||||
| 5/5/26 |  London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors | Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR program is preparing to go into the clinic. | — | ||||||
Showing 25 of 459
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for BiotechTV - News
Peaked at #45 in VN, currently #45 in VN.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| VN | — | #45 | #45 | — |
| Sweden | — | #47 | #47 | — |
| SG | — | #47 | #47 | — |
| GR | — | #54 | #54 | — |
| IL | — | #61 | #61 | — |
| Spain | — | #62 | #62 | — |
| United States | — | #79 | #79 | — |
| HK | — | #80 | #80 | — |
| South Korea | — | #84 | #84 | — |
| BE | — | #109 | #109 | — |
| India | — | #117 | #117 | — |
| Ireland | — | #118 | #118 | — |
| CZ | — | #119 | #119 | — |
| Denmark | — | #120 | #120 | — |
| PT | — | #129 | #129 | — |
| Japan | — | #132 | #132 | — |
| United Kingdom | — | #146 | #146 | — |
| AT | — | #146 | #146 | — |
| Netherlands | — | #147 | #147 | — |
| TW | — | #154 | #154 | — |
Chart Positions
20 placements across 20 markets.
Chart Positions
20 placements across 20 markets.